(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 December 2005 (01.12.2005)

PCT

(10) International Publication Number
WO 2005/112568 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2005/015531

(22) International Filing Date: 4 May 2005 (04.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/568,371 4 May 2004 (04.05.2004) US

(71) Applicant *(for all designated States except US)*: **GENAISSANCE PHARMACEUTICALS, INC.** [US/US]; Five Science Park, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KOSHY, Beena** [IN/US]; 66 Rockford Avenue, Hamden, CT 06514 (US). **DAIN, Bradley, J.** [US/US]; 10 Ted's Court, Cheshire, CT 06410 (US). **ANANT, Madan, Kumar** [US/US]; 10 Ted's Court, Cheshire, CT 06410 (US). **ZHAN, Ping** [CN/US]; 105 Harbour Close, New Haven, CT 06519 (US).


(74) Agent: **COX, Niki, D.**; Biogen Idec Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: HAPLOTYPE MARKERS AND METHODS OF USING THE SAME TO DETERMINE RESPONSE TO TREATMENT



(57) Abstract: The present invention relates to methods for diagnosing or predicting responsiveness to treatment, such as Alefacept, by determining the presence of a nucleotide at one or more polymorphic sites within a haplotype marker. The present invention identifies multiple haplotypes that are associated with response to Alefacept. The haplotype markers identified by the present invention and methods of the invention can be particularly useful for diagnosing or predicting susceptibility to skin diseases, such as Psoriasis.

WO 2005/112568 A2

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.